EUCTR2014-003177-42-SI进行中（未招募）1 期
Multinational study assessing the acceptability and determinants of compliance to HPV vaccination to women in screening ages 25 to 45 years
Catalan Institute of Oncology0 个研究点目标入组 3,250 人开始时间: 2016年3月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 3,250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Adult women within the age range of 25-45 attending cervical cancer screening with no previous history of HPV vaccine administration.
- •In Spain, also, women aged 35-45 yrs old with no screening record in the preceding 5 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 3250
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Known history of severe allergic reaction or hypersensitivty to any of the components of the HPV vaccines.
- •2. Known history of immune-related disorders
- •3. Current acute severe febrile illness, except for minor infections such as a cold, mild upper respiratory infection or low-grade fever. When recovered, the vaccine can be administered
- •4. Administration of immunoglobulin or blood-derived products within 6 months prior to scheduled HPV vaccine first dose
- •5. Current pregnancy (reported), breast-feeding or planning to get pregnant in the coming 12 months.
- •6. Hysterectomized women
研究者
相似试验
进行中（未招募）
1 期
Study in several countries to assess the proportion of adult women (25-45 yrs) who accept to receive the HPV vaccine, the reasons to accept it and how many of these women receive the three doses and why.MedDRA version: 17.1Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10056576Term: Cervical intraepithelial neoplasiaSystem Organ Class: 100000004872Cervical cancerEUCTR2014-003177-42-BEGhent University Hospital3,250
进行中（未招募）
1 期
Study in several countries to assess the proportion of adult women (25-45 yrs) who accept to receive the HPV vaccine, the reasons to accept it and how many of these women receive the three doses and why.Cervical cancerEUCTR2014-003177-42-FICatalan Institute of Oncology3,648
进行中（未招募）
1 期
Study in several countries to assess the proportion of adult women (25-45 yrs) who accept to receive the HPV vaccine, the reasons to accept it and how many of these women receive the three doses and why.MedDRA version: 17.0Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10056576Term: Cervical intraepithelial neoplasiaSystem Organ Class: 100000004872Cervical cancerEUCTR2014-003177-42-ESCatalan Institute of Oncology3,250
进行中（未招募）
1 期
Study in several countries to assess the proportion of adult women (25-45 yrs) who accept to receive the HPV vaccine, the reasons to accept it and how many of these women receive the three doses and why.MedDRA version: 19.0Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10056576Term: Cervical intraepithelial neoplasiaSystem Organ Class: 100000004872Cervical cancerEUCTR2014-003177-42-NLCatalan Institute of Oncology3,648
撤回
4 期
Multinational study assessing the acceptability and determinants of compliance to HPV vaccination to women in screening ages 25 to 45 yearsNL-OMON44098Vrije Universiteit Medisch Centrum250